2 news items
Arrowhead Pharmaceuticals Earns $50M Milestone From Royalty Pharma, Pursuant To Its 2016 Agreement With Amgen And 2022 Agreement With Royalty Pharma, Arrowhead Is Further Eligible To Receive Up To An Additional $375M From Amgen And $110M From Royalty Pharma In Aggregate Development, Regulatory, And Sales Milestone Payments Associated With Olpasiran
AMGN
ARWR
RPRX
2 May 24
, to placebo, on the risk for coronary heart disease death, myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a).
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
AMGN
ARWR
RPRX
2 May 24
disease death, myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease and elevated
- Prev
- 1
- Next